Last reviewed · How we verify

Dihydrex (BENZTHIAZIDE)

Ah Robins Inc · FDA-approved approved Small molecule

Dihydrex works by inhibiting the sodium-chloride cotransporter in the kidneys, reducing sodium reabsorption and increasing sodium excretion.

Dihydrex (BENZTHIAZIDE) is a small molecule drug in the benzthiazide class, originally developed by AH ROBINS INC and currently owned by the same company. It targets the solute carrier family 12 member 3 and was FDA approved in 1960 for treatment of hypertension. As an off-patent medication, Dihydrex is available as a generic product from a single manufacturer. Key safety considerations include its bioavailability of 25%. Dihydrex is used to treat hypertension.

At a glance

Generic nameBENZTHIAZIDE
SponsorAh Robins Inc
Drug classbenzthiazide
TargetCalcium-activated potassium channel subunit alpha-1, Carbonic anhydrase 1, Carbonic anhydrase 2
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved
First approval1960

Mechanism of action

Think of it like a sponge: when you squeeze a sponge, water comes out. Dihydrex helps the kidneys squeeze out excess sodium and water, which can help lower blood pressure. This is especially helpful for people with high blood pressure, as it can reduce the strain on the heart and blood vessels.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: